Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 29;13(3):678-683.
doi: 10.21037/tlcr-23-793. Epub 2024 Mar 18.

Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells

Roberta Mazza  1 , John Maher  1   2   3 , Caroline M Hull  1
Affiliations
Editorial

Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells

Roberta Mazza et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Delta-like ligand 3 (DLL3); armoured CAR T-cells; immunotherapy; interleukin-18-secreting chimeric antigen receptor T-cells (IL-18-secreting CAR T-cells); small-cell lung cancer (SCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-793/coif). C.M.H. and R.M. are employees of Leucid Bio Ltd. J.M. is the founder, Chief Scientific Officer and shareholder of Leucid Bio Ltd. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Mechanisms that promote tumour clearance by IL-18 secreting CAR T-cells. CAR, chimeric antigen receptor; IFN, interferon; TNF, tumour necrosis factor; IL, interleukin; Treg, regulatory T cell; NK, natural killer; DC, dendritic cell.
See this image and copyright information in PMC

Comment on

References

    1. Maher J. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives. Onco Targets Ther 2023;16:515-32. 10.2147/OTT.S341179 - DOI - PMC - PubMed
    1. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 2021;7:3. 10.1038/s41572-020-00235-0 - DOI - PMC - PubMed
    1. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7:100408. 10.1016/j.esmoop.2022.100408 - DOI - PMC - PubMed
    1. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol 2020;15:426-35. 10.1016/j.jtho.2019.10.004 - DOI - PubMed
    1. Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol 2018;4:1569-75. 10.1001/jamaoncol.2018.3039 - DOI - PMC - PubMed